[Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency]

Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(9):35-9.
[Article in Russian]


A complex clinical-instrumental study included 138 patients with discirculatory encephalopathy (DE) who received cavinton perorally in dose 30 mg/day during 90 days (2 courses in a year) in addition to the basic therapy (hypotensive and antithrombotic drugs, neuroprotector glycine). A control group comprised 98 patients clinically matched with the main group. They received only basic therapy. Neurological status and results of neuropsychological tests were assessed before treatment and to the end of 3, 6 and 12 months. The improvement of all neurological syndromes studied was seen in the main group to the end of 12 months as compared to controls. The complex treatment using cavinton led to the significant decrease of risk of DE progression, development of transitory ischemic attacks and strokes compared to controls (relative risks were 0,01 and 0,14, respectively).

Publication types

  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / administration & dosage*
  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / physiopathology
  • Cognition / physiology
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Motor Activity / physiology
  • Treatment Outcome
  • Vinca Alkaloids / administration & dosage*


  • Calcium Channel Blockers
  • Vinca Alkaloids
  • vinpocetine